Stock COH COCHLEAR LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Cochlear Limited

Equities

COH

AU000000COH5

Market Closed - Australian S.E.
Other stock markets
 02:10:44 2024-04-26 am EDT 		5-day change 1st Jan Change
320.8 AUD +0.24% Intraday chart for Cochlear Limited +1.62% +7.40%
Apr. 22 Cochlear Limited Announces Company Secretary Changes CI
Apr. 19 Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cochlear Limited Announces Company Secretary Changes
CI
Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old
CI
ACCC will not oppose revised Cochlear, Oticon Medical transaction
AQ
Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business
MT
Miners, healthcare firms push Australia stocks higher
RE
Ex-dividend day for interim dividend
FA
Sensorion: study results in hearing loss
CF
Morgan Stanley Adjusts Cochlear’s Price Target to AU$276 From AU$258, Keeps at Underweight
MT
Jarden Research Adjusts Cochlear’s Price Target to AU$244.35 From AU$237.17, Keeps at Neutral
MT
Cochlear's Revenue Soars on Sales Growth
MT
Australian Shares Flat as Mining, Financials Rally Offset Other Sectors' Losses
MT
Cochlear Shares Slip 2%; Expects 26% Rise in Full Year Net Profit After Increase in H1 FY24 Profit, Revenue
MT
Transcript : Cochlear Limited, H1 2024 Earnings Call, Feb 19, 2024
Cochlear Posts Rise in H1 FY24 Profit, Revenue
MT
Correction: --Cochlear Reports Half Year FY24 Revenue Up 24% to AU$1.1 Billion; EPS of AU$2.913
MT
Cochlear Reports Half Year FY24 Revenue Up Down 24% to AU$1.1 Billion; EPS of AU$2.913
MT
Tranche Update on Cochlear Limited's Equity Buyback Plan announced on February 15, 2023.
CI
Cochlear Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Cyclopharm Appoints CFO; Shares Rise 3%
MT
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12)
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. COH Stock
  4. News Cochlear Limited